This randomized clinical trial of an NT-proBNP–guided approach to neurohormonal therapy in patients with cancer treated with anthracyclines demonstrates the feasibility, safety, and potential modest, early improvement in LVEF of a biomarker-guided approach. The gene discussed is NPPB; the disease is cancer.